CATALYST DOSSIER · UPDATED 2026-11-10
$COCH
biotech · convergence -6 · conviction WATCH
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $COCH?
Quantitative
Convergence score : -6 (7 signals firing YoY)
Catalysts
Multi-spoke convergence : 7 convergent signals fired: auto_macro_adp_payrolls, auto_macro_banrep_colombia, auto_macro_bls_employment, auto_macro_credit_spreads, auto_macro_durable_goods
Risks
Position-sizing discipline : Conviction WATCH (-6 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Multiple compression : If breadth deteriorates, biotech-wide multiples re-rate lower regardless of pick-specific thesis
Sympathy basket (cerebro)
QBTS via tech r=+0.97 sympathetic (score 25)
INVE via tech r=+0.97 sympathetic (score 24)
GCTS via semis r=+0.91 sympathetic (score 28)
NVDA via semis r=+0.91 sympathetic (score 27)
MOD via consumer r=+0.81 sympathetic (score 23)
LINC via consumer r=+0.81 sympathetic (score 18)
Signals Firing
auto_macro_adp_payrolls auto_macro_banrep_colombia auto_macro_bls_employment auto_macro_credit_spreads auto_macro_durable_goods auto_macro_options_gex auto_macro_yield_curve
Pick Track Record Date List Next-day max run Next-day close Hit +2%? 2026-10-07 sec_top_gappers +2.6% +0.8% ✓ hit 2026-10-07 sec_top_moat_emerging +2.6% +0.8% ✓ hit 2026-09-14 sec_top_gappers +4.1% -2.7% ✓ hit 2026-09-14 sec_top_moat_emerging +4.1% -2.7% ✓ hit
Lifetime: 4/4 wins · hit-rate 100.0% on +2% intraday
Sympathy Basket QBTS via tech · score 25 INVE via tech · score 24 GCTS via semis · score 28 NVDA via semis · score 27 MOD via consumer · score 23 LINC via consumer · score 18
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.